miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1

Huanxin Liu*,†, Xiaoxia Wu†, Jie Huang*, Juan Peng* and Linlang Guo*
*Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China and †Department of Pathology, Guangdong Provincial Corps Hospital of Chinese People’s Armed Police Forces, Guangzhou medical college, Guangzhou, China

SUMMARY

MicroRNAs (miRNAs) represent a class of small non-coding RNAs and have been shown to play important roles in various biological processes including cell growth, differentiation and apoptosis by regulating the target genes. miR-7 has been described not only as a tumour suppressor gene but also as an oncogene in human cancers. The aim of this study was to investigate the functional roles of miR-7 in chemoresistance of SCLC and its underlying mechanism. By using a bioinformatic assay, we found that MRP1/ABCC1 was a potential target gene of miR-7. Expression of miR-7 and MRP1/ABCC1 was examined in 44 SCLC samples by quantitative reverse transcription–polymerase chain reaction and immunohistochemistry methods. Low-level expression of miR-7 was associated significantly with drug responsiveness and overall survival rate of patients with SCLC, but not with gender, age and stage. There was an inverse relationship between miR-7 and MRP1/ABCC1 expression. Downregulation of MRP1/ABCC1 level was revealed after transfection with a miR-7 mimic in H69 AR cells. Transfection of a miR-7 inhibitor into H69 cells restored MRP1/ABCC1 expression. A dual-luciferase reporter assay confirmed that miR-7 targeted predicted sites in the 3'-untranslated region (3'-UTR) of the MRP1/ABCC1 gene. Our data suggested that miR-7 mediated SCLC chemoresistance by repressing MRP1/ABCC1 and may be a prognostic predictor and potential therapeutic target in human SCLC.

Keywords
chemoresistance, miR-7, MRP1/ABCC1, SCLC

Small cell lung cancer (SCLC), accounting for approximately 15% of all human lung cancers, is an aggressive malignant tumour (Govindan et al. 2006). Chemotherapy remains the first treatment approach for patients with SCLC including platinum and etoposide. Although most of the patients with SCLC are responsive to chemotherapy, their 2-year survival rate is <5% because drug resistance emerges and leads to high propensity for relapse (Sandler 2003). Therefore, chemoresistance has become one of the major obstacles in the treatment, and a detailed understanding of the molecular mechanism associated with chemoresistance is crucial for improving current therapeutic strategies for SCLC.

MicroRNAs (miRNAs) are a cluster of endogenous phyletically conserved small non-coding RNA molecules, which are 18–24 nucleotides in length. They regulate gene expression via binding to the 3'-untranslated region (3'-UTR) of their target mRNA, leading to negative post-transcriptional translation or to degradation of the target mRNA (Bartel 2004). Many studies have shown that aberrantly expressed miRNAs could affect cell biological activities such as cell proliferation, apoptosis and cancer development. Recently, some miRNAs have been proved to be closely relevant to the drug sensitivity or resistance (Yang et al. 2008; Fornari et al. 2009; Song et al. 2009; Valeri et al. 2010; Rao et al. 2011; Xiao et al. 2014). Our previous miRNA expression profile has shown that miR-7 expression markedly decreased in SCLC multidrug-resistant cells (H69AR) as compared to parental H69 cells by microarray and qRT-PCR (Guo et al. 2010). However, there is still no report available about miR-7 functions in SCLC drug resistance.

Multidrug resistance-associated protein 1 (MRP1), also named as ABCC1, is a member of the ATP-binding cassette transporter superfamily, which includes 49 members distributed in 7 subfamilies from ABCA to ABCG (Mo & Zhang 2009; Yin & Zhang 2011). MRP1/ABCC1, as an...
ABCC1 was identified as a direct downstream target of miR-7. SCLC-resistant cell line (H69AR). Furthermore, MRP1/ABCC1 plays an important role in chemoresistance using the cellular model of a human with SCLC. We then further investigated the potential miR-7 relevance of its expression with clinical prognosis of patients expression of miR-7 in SCLC tissues and evaluated the resistance of SCLC and its underlying mechanism, we detected the presence of SCLC. Overexpression of MRP1/ABCC1 was predictive of poor response to chemotherapy in SCLC (Hsia et al. 2002; Kuo et al. 2003; Triller et al. 2006). We also previously showed that MRP1/ABCC1 is closely related to chemoresistance in SCLC (Guo et al. 2010). It has been demonstrated that some miRNAs can directly target and regulate MRP1/ABCC1 expression (Liang et al. 2010; Fang et al. 2012). In our previous study, we showed that MRP1/ABCC1 is negatively regulated by miR-134 and that downregulation of MRP1/ABCC1 at the protein level largely correlates with elevated levels of miR-134 in H69AR cells. Upregulation of MRP1/ABCC1 is also associated with some other miRNAs such as miR-326, miR-199a, miR-199b and miR-296. By using a bioinformatic assay, we found that the 3′-UTR of human MRP1/ABCC1 contains putative regions that match to the seed sequence of miR-7 and not to the other miRNAs stated above, which suggests a possible modulation of MRP1/ABCC1 by miR-7.

To investigate the functional roles of miR-7 in chemoresistance of SCLC and its underlying mechanism, we detected the expression of miR-7 in SCLC tissues and evaluated the relevance of its expression with clinical prognosis of patients with SCLC. We then further investigated the potential miR-7 role in chemoresistance using the cellular model of a human SCLC-resistant cell line (H69AR). Furthermore, MRP1/ABCC1 was identified as a direct downstream target of miR-7.

Cell Lines

Human SCLC cell line NCI-H69 and the drug-resistant subline H69AR were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI 1640 medium containing L-glutamine with 10% and 20% foetal calf serum, respectively, in an incubator at 37°C with 5% CO2.

Cell transfection

Cells were transiently transfected with 100 nmol/l of miR-7 mimics, inhibitors and miRNA negative control (miR-NC) (Bioneer, Daejeon, Korea) using Lipofectamine 2000 and OPTI-MEM I (Invitrogen USA, Carlsbad, California). Infection efficiency was confirmed by fluorescent quantitative PCR and Western blotting.

RNA isolation, reverse transcription and quantitative real-time PCR

Total RNA, including miRNAs, was isolated from cell lines and FFPE tissues using TRIzol (Invitrogen USA, Carlsbad, California), miRNeasy kit (Qiagen, Hilden, Germany) and miRNeasy FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA synthesis was carried out according to PrimeScript RT reagent Kit (Takara, Dalian, China). The miRNA sequence-specific reverse transcription–qRT-PCR for miR-7 and endogenous control U6 were performed according to Hairpin-it™ miRNAs qRT-PCR quantitation kit and U6 snRNA real-time PCR normalization kit (GenePharma, Shanghai, China). GAPDH or U6 snRNA was used as an endogenous control.

Immunohistochemical analysis

Formalin-fixed, paraffin-embedded tissues of SCLC clinical patient samples were sectioned at 4 μm thickness and analyzed for MRP1/ABCC1 (1:200 dilutions, Alomone Labs Ltd., Jerusalem, Israel) expression. Visualization was achieved using the EnVision peroxidase system (Dako, Dusseldorf, Germany). A sample was considered positive if more than 50% of the tumour cells retained cytoplasm staining, and 5 fields were randomly selected according to semiquantitative scales. The intensity of staining was scored manually (high, 3; medium, 2; low, 1; no staining, 0) by two independent experienced pathologists, and only tumour cells were scored. Negatively stained MRP1/ABCC1 was considered positive if <50% of the tumour cells retained cytoplasm staining. Negative controls were performed by replacing the primary antibodies stated above with PBS.

Luciferase reporter assay

Cells were seeded in a 48-well plate and cotransfected with 200 ng of either pcDNA/miR-7 or pcDNA/miR-NC vectors, and 10 ng of pLUC vectors containing firefly luciferase
reporter gene, as well as the 3′-UTR of ABCC1 gene. Cells were harvested for luciferase activity assays 48 h after transfection. A luciferase assay kit (Promega, Madison, WI, USA) was used according to the manufacturer’s protocol. The assay was conducted in five replicate wells for each sample and three parallel experiments were performed.

**Statistical analysis**

All experiments were run in triplicate. The results were given as mean ± SD. Statistical analyses were performed using either an analysis of variance (ANOVA) or Student’s t-test. The relationship between MRP1/ABCC1 and miR-7 expressions was explored by Pearson correlation. The difference was considered statistically significant when the P value was <0.05. All statistical analyses were carried out with SPSS 13.0 (Armonk, New York, USA) software. All assay were conducted in three parallel experiments were performed.

**Results**

**Expression of miR-7 and MRP1/ABCC1 and their correlations with clinicopathological characteristics in SCLC**

Expression of miR-7 and MRP1/ABCC1 was analysed, respectively, by qRT-PCR and IHC in 44 samples from patients with SCLC. As shown in Table 1, miR-7 expression was shown to correlate significantly with drug responsiveness. However, there was no significant relationship between miR-7 expression and gender, age or clinical stage. Similar results were also observed in MRP1/ABCC1 expression. MRP1/ABCC1 expression was localized on the membrane of the cancer cells. (Figure 1) The positive rate of MRP1/ABCC1 expression was 20% in drug-sensitive SCLC specimens, which was significantly lower than that (75%) in drug-resistant SCLC specimens. The median value of all 44 SCLC cases was chosen as the cut-off point for separating tumours with low-level expression of miR-7 from high-level expression miR-7 tumours. A higher expression level of miR-7 was found in the drug-sensitive group than in the drug-resistant group. In addition, Kaplan–Meier analysis revealed that low-level expression of miR-7 was significantly associated with shorter overall survival (OS) rate (P = 0.048; Figure 2). However, multivariate Cox regression analysis indicated that miR-7 and ABCC1 are not independent prognostic factors for survival of patients with SCLC (P > 0.05; Table 2).

**MRP1/ABCC1 expression is correlated with miR-7 in SCLC tissues**

To further evaluate the relationship between MRP1/ABCC1 and miR-7 in SCLC tissues, we measured miR-7 expression level in MRP1/ABCC1-positive SCLC specimens and MRP1/ABCC1-negative specimens which were examined by IHC.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>Low</th>
<th>High</th>
<th>P*</th>
<th>–</th>
<th>+</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38</td>
<td>19</td>
<td>19</td>
<td>1.000</td>
<td>19</td>
<td>19</td>
<td>1.000</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>22</td>
<td>13</td>
<td>9</td>
<td>0.228</td>
<td>13</td>
<td>9</td>
<td>0.228</td>
</tr>
<tr>
<td>≥55</td>
<td>22</td>
<td>9</td>
<td>13</td>
<td></td>
<td>9</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited</td>
<td>20</td>
<td>9</td>
<td>11</td>
<td>0.545</td>
<td>8</td>
<td>12</td>
<td>0.226</td>
</tr>
<tr>
<td>Extensive</td>
<td>24</td>
<td>13</td>
<td>11</td>
<td></td>
<td>14</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Drug sensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitive group</td>
<td>20</td>
<td>7</td>
<td>13</td>
<td>0.027</td>
<td>16</td>
<td>4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Resistant group</td>
<td>20</td>
<td>14</td>
<td>6</td>
<td></td>
<td>5</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>

*, negative; +, positive.

*, Negative stained MRP1/ABCC1 was considered positive if <50% of the tumour cells retained cytoplasm staining; +, positive stained MRP1/ABCC1 was considered positive if more than 50% of the tumour cells retained cytoplasm staining.

*The median expression level was used as the cut-off. Low expression of miR-7 patients was classified as values of 2^−ΔΔct below 1.0. High miR-7 expression in patients was classified as values of 2^−ΔΔct above 1.0.

†For the analysis of correlation between miR-7 and ABCC1 levels and clinical features, chi-square test was used. Results were considered statistically significant at P < 0.05.
Figure 2 Kaplan–Meier analysis of overall survival of 44 patients with SCLC based on miR-7 expression.

Table 2 Univariate and multivariate analyses of overall survival with regard to clinicopathological characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Univariate Analysis</th>
<th>Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR(95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Gender</td>
<td>0.705 (0.206–2.414)</td>
<td>0.578</td>
</tr>
<tr>
<td>Age</td>
<td>0.452 (0.178–1.152)</td>
<td>0.096</td>
</tr>
<tr>
<td>Stage</td>
<td>1.555 (0.621–3.892)</td>
<td>0.346</td>
</tr>
<tr>
<td>Drug sensitivity</td>
<td>1.732 (0.724–4.140)</td>
<td>0.217</td>
</tr>
<tr>
<td>MiR-7</td>
<td>0.399 (0.153–1.037)</td>
<td>0.059</td>
</tr>
<tr>
<td>ABCC1</td>
<td>1.635 (0.677–3.950)</td>
<td>0.274</td>
</tr>
</tbody>
</table>

Figure 3 (a) The expression and relationship of miR-7 and MRP1/ABCC1 in SCLC tissues. The expression levels of miR-7 ($\Delta$Ct value) in MRP1/ABCC1-negative ($n=22$) and MRP1/ABCC1-positive SCLC tissues ($n=22$). (b) The correlation of miR-7 and MRP1/ABCC1 expression in tissues.
MRP1/ABCC1 is the target of miR-7. Expression of miR-7 was detected after transfection with miR-7 mimics (a) and inhibitor (b) in sH69 cells and H69AR cells by qRT-PCR.; MRP1/ABCC1 mRNA level (c) and protein level (e) were assessed 72 h after transfection with miR-7 mimics and negative controls in H69AR cells. SCGN mRNA level (d) and protein level (f) were assessed 72 h after transfection of miR-7 inhibitors and negative controls in H69 cells. **P < 0.001 compared with control.

Figure 4 (a) The electrophoresis analyses of PCR product on agarose gels. 1, the PCR product of ABCC1-3'UTR, 779 bp; 2, the PCR product of ABCC1-3'UTR-R, 780 bp; M, DNA marker. (b) Dual-luciferase assay was performed in H69 cells transfected with luciferase construct alone or cotransfected with miR-7 agomir and antagonir. **P < 0.01.

Figure 5 MRP1/ABCC1 is the target of miR-7. Expression of miR-7 was detected after transfection with miR-7 mimics (a) and inhibitor (b) in sH69 cells and H69AR cells by qRT-PCR.; MRP1/ABCC1 mRNA level (c) and protein level (e) were assessed 72 h after transfection with miR-7 mimics and negative controls in H69AR cells. SCGN mRNA level (d) and protein level (f) were assessed 72 h after transfection of miR-7 inhibitors and negative controls in H69 cells. **P < 0.001 compared with control.
The expression of miR-7 decreased significantly in MRP1/ABCC1-positive SCLC samples compared with MRP1/ABCC1-negative tissues (Figure 3a). The results suggest that miR-7 was negatively correlated with MRP1/ABCC1 expression in SCLC tissues ($r = -0.844, p < 0.001$; Figure 3b).

**MiR-7 directly targets MRP1/ABCC1 in SCLC**

It is generally accepted that miRNAs exert their functions through activation or repression of the downstream target genes. By searching PicTar, TargetScan and miRBase databases, we found that the 3’UTR of human MRP1/ABCC1 contains putative regions that match to the seed sequence of miR-7. Based on above statistical results and bioinformatic prediction, we hypothesized that MRP1/ABCC1 may be a target of miR-7 in SCLC.

To verify whether MRP1/ABCC1 is a direct target of miR-7, we constructed luciferase reporter vectors with wild-type (psiCHECK2-ABCC1-wt) or mutated (psiCHECK2-ABCC1-mt) 3’UTR of MRP1/ABCC1 gene. Then, either vector was cotransfected with miR-7 agomir or antagomir in H69 cells. The results of dual-luciferase reporter assays showed that miR-7 agomir can suppress luciferase activity when cotransfected with wild-type reporter vector. Moreover, miR-7 antagonist led to an increase in luciferase activity, and the activity of mutated reporter vector was unaffected by a simultaneous transfection with miR-7 agomir or antagonist. (Figure 4) Taken together, all these findings suggested that miR-7 directly targets MRP1/ABCC1 in SCLC. To further evaluate whether miR-7 can affect the endogenous expression of MRP1/ABCC1, we examined MRP1/ABCC1 expression after knockdown or upregulation of miR-7 using miR-7 mimic or inhibitor, respectively. Downregulation of MRP1/ABCC1 level was revealed after transfection with miR-7 mimic in H69AR cells. Transfection of miR-7 inhibitor in H69 cells restored MRP1/ABCC1 expression (Figure 5a–e).

**Discussion**

Chemotherapy is still the chief treatment for patients with SCLC, and multidrug resistance (MDR) is one of the most important factors that hinder the outcomes (Liang et al. 2010). Although deregulation of miRNAs has been reported to be associated with MDR in various cancers (Zaman et al. 1993; Flens et al. 1996; St-Pierre et al. 2000; Chang 2007; Yin & Zhang 2011), the molecular mechanisms by which miRNAs modulate drug resistance are still unclear.

miR-7 has been described as a tumour suppressor gene in several human cancers including glioblastoma, hepatocellular carcinoma, lung cancer and gastric tumours (Kefas et al. 2008; Xiong et al. 2011; Fang et al. 2012; Kong et al. 2012; Li et al. 2014), however, also as a oncogene in breast cancer and renal cell carcinoma (Moitra et al. 2012; Yu et al. 2013). miR-7 functions as a tumour suppressor gene by directly targeting or indirectly downregulating central oncogenic factors including epidermal growth factor receptor (EGFR), p21-activated kinase 1 (PAK1) and other genes (Reddy et al. 2008; Saydam et al. 2011; Skalsky & Cullen 2011). However, to our knowledge, the functional roles of miR-7 in chemoresistance have not been reported yet. In this study, we examined miR-7 expression in 44 SCLC samples and its correlation with clinicopathological feature. The results showed that the expression level of miR-7 was downregulated in the drug-resistant group compared with that in the drug-sensitive group, and miR-7 expression was closely correlated with chemotherapy responsiveness, but not with gender, age and clinical stage of patients with SCLC. Similarly to previous researchers, we found low-level expression of miR-7 was associated significantly with shorter OS rate, but multivariate Cox regression analysis indicated that miR-7 is not an independent prognostic factor for survival of patients with SCLC. These finding suggested that miR-7 might be a predictive marker for chemosensitivity in SCLC.

MRP1/ABCC1 is the first gene to be characterized in the ABCC subfamily and was originally identified as being responsible for the multidrug resistance phenotype in a drug-selected human small cell lung cancer cell line H69AR (Cole et al. 1992). Several researchers have indicated that MRP1/ABCC1 has a role in the clinical drug resistance behaviour of SCLC and was predictive of response to chemotherapy (Hsia et al. 2002; Kuo et al. 2003). Correlation analysis between ABC and miRNA expression in individual patients revealed an inverse relationship, confirming an indication for miRNA regulation of ABC genes in HCC 13 cellular miRNAs that target ABCA1, ABC1, ABC5, ABCC10 and ABCE1 genes and mediate changes in gene expression (Borel et al. 2012). In breast cancer, elevated levels of miR-326 in the mimic-transfected VP-16-resistant cell line MCF-7/VP downregulated MRP-1/ABCC1 expression and sensitized these cells to VP-16 and doxorubicin (Liang et al. 2010). Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1 (Pan et al. 2013). But the molecular mechanism of MRP1/ABCC1 in MDR of SCLC remains unknown. We analysed the expression of MRP1/ABCC1 in 44 cases of human SCLC tissues by IHC staining. Contrary to miR-7, the positive rate of MRP1/ABCC1 expression was significantly lower in drug-sensitive SCLC specimens than that in drug-resistant specimens. In addition, MRP1/ABCC1 expression was closely correlated with chemotherapy response, but not with gender, age and stage of patients with SCLC.

It has been reported that some genes are the direct targets of miR-7. The above data showed MRP1/ABCC1 expression was negatively correlated with miR-7 level in SCLC tissues. To determine whether MRP1/ABCC1 is a direct target of miR-7, we searched potential targets of miR-7 in PicTar, TargetScan and miRBase databases and found that the 3’UTR of human MRP1/ABCC1 contains putative regions that match to the seed sequence of miR-7. Forced expression of miR-7 inhibits
MRP1/ABCC1 expression in H69AR cells, and knockdown of miR-7 elevates MRP1/ABCC1 expression in H69 cells. Dual-luciferase assays verified MRP1/ABCC1 as a direct target of miR-7. These findings indicated that miR-7 modulates chemosensitivity of SCLC through the regulation of MRP1/ABCC1.

In summary, our study showed that low-level of miR-7 expression was closely associated with chemotherapy resistance and shorter overall survival. These findings suggest miR-7 may serve as predictive biomarker for chemoresistance and prognostic biomarker for survival in patients with SCLC. Furthermore, we demonstrated that miR-7 mediated chemoresistance by repressing MRP1/ABCC1, which is a novel mechanism of chemoresistance in SCLC, suggesting that miR-7 (MRP1/ABCC1) could be employed as an effective therapeutic target for SCLC.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgements
This work was supported in part by the National Natural Science Foundation of China (81041068, 30971183).

References


